The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 31, 2022
Filed:
Oct. 28, 2019
Applicant:
Reven Ip Holdco Llc, Golden, CO (US);
Inventors:
Hendrik J. P. van Wyk, Broomfield, CO (US);
Peter B. Lange, Golden, CO (US);
James Ervin, Novi, MI (US);
Brian D. Denomme, Northville, MI (US);
Mariette L. van Wyk, Broomfield, CO (US);
Peter Pacult, Denver, CO (US);
Michael A. Volk, Broomfield, CO (US);
Assignee:
REVEN IP HOLDCO LLC, Golden, CO (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/375 (2006.01); A61P 3/00 (2006.01); A61K 47/02 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/19 (2006.01); A61K 31/122 (2006.01); A61K 31/197 (2006.01); A61K 31/4415 (2006.01); A61K 31/455 (2006.01); A61K 31/51 (2006.01); A61K 31/675 (2006.01); A61K 31/714 (2006.01); A61K 33/20 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/375 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 9/08 (2013.01); A61K 9/19 (2013.01); A61K 31/122 (2013.01); A61K 31/197 (2013.01); A61K 31/4415 (2013.01); A61K 31/455 (2013.01); A61K 31/51 (2013.01); A61K 31/675 (2013.01); A61K 31/714 (2013.01); A61K 33/20 (2013.01); A61K 47/02 (2013.01); A61P 3/00 (2018.01); A61K 45/06 (2013.01);
Abstract
The present invention relates to stable therapeutic compositions of pharmaceutical grade acids and pH buffering agents. The present invention also is directed to methods of treatment for mitochondrial disorders, metabolic conditions, diabetic conditions, and cardiovascular conditions, by administration of compositions of the present disclosure.